Oragends在试验阶段2a之前完成脑震荡药物的鼻腔装置配方,ONP-002。 Oragenics completes nasal device formulation for concussion drug ONP-002 ahead of Phase 2a trial.

生物技术公司Oragenics Inc.已经完成了其主要候选药物ONP-002的鼻腔装置的喷雾干燥配方和填充，针对脑震荡。 Oragenics Inc., a biotech company, has finished spray-dried formulation and filling of its nasal device for its lead candidate ONP-002, targeting concussions. 预填配方用于即将进行的第二阶段临床试验,40名脑震荡病人接受了临床试验,受伤后每天两次服用1:1安慰剂或ONP-002药物,为期五天。 The prefilled formulation is for the upcoming Phase 2a clinical trial enrolling 40 concussed patients, with 1:1 placebo or ONP-002 drug given twice daily for five days following injury. 该试验旨在在受伤8小时内开始治疗,并包括患者报告的结果和血液生物标志物进行评估. The trial aims to start treatment within 8 hours of injury and includes patient-reported outcomes and blood biomarkers in evaluation.